This compounded topical cream combines Cyclosporine A 2%, Ketoprofen 2.5%, and Phenylephrine HCl 0.1% in a semisolid preparation dispensed in a convenient pump mechanism. Designed for controlled and localized application on the skin, this formulation aims to deliver a synergistic effect by integrating the immunomodulatory, anti-inflammatory, and vasoconstrictive properties of its active ingredients.

Cyclosporine A is an immunosuppressive agent known for its ability to inhibit the activity of T-lymphocytes, essential components of the immune system. When applied topically, it can help reduce inflammation and alleviate symptoms associated with autoimmune and inflammatory skin conditions by modulating the immune response at the application site.

Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that provides analgesic and anti-inflammatory effects. By inhibiting the cyclooxygenase enzymes COX-1 and COX-2, Ketoprofen reduces the synthesis of prostaglandins, which are mediators of pain and inflammation. Its inclusion in the cream helps alleviate pain and reduce inflammation in affected areas.

Phenylephrine HCl is a selective alpha-1 adrenergic receptor agonist that causes vasoconstriction. Topically applied, it can decrease local blood flow, reducing redness and

Cyclosporine A 2%/Ketoprofen 2.5%/Phenylephrine HCl 0.1% Topical Cream is a compounded formulation designed for localized treatment and absorption of active ingredients through the skin. This formulation combines the immunosuppressive properties of Cyclosporine A, the anti-inflammatory effects of Ketoprofen, and the vasoconstrictive action of Phenylephrine HCl. While this combination can be effective for treating certain disease states, it is important to be aware of potential drug interactions that may affect the safety and efficacy of the treatment.

Cyclosporine A is a potent immunosuppressant that can interact with a wide range of medications. It is metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system, and concurrent use of drugs that inhibit or induce this enzyme can alter cyclosporine levels. Inhibitors of CYP3A4, such as ketoconazole, erythromycin, and grapefruit juice, can increase cyclosporine levels, potentially leading to toxicity. Conversely, inducers like rifampin and St. John's Wort can decrease cyclosporine levels, reducing its efficacy. Patients should be monitored for signs of cyclosporine toxicity, such as nephrotoxicity and hypertension, and dosage adjustments may be necessary.

Ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID), can interact with other medications that affect renal function or increase the risk of gastrointestinal bleeding. Concurrent use with other NSAIDs, anticoagulants like warfarin, or antiplatelet agents such as aspirin can increase the risk of bleeding. Additionally, ketoprofen may reduce the antihypertensive effects of certain blood pressure medications, including ACE inhibitors and beta-blockers. Patients should be advised to report any signs of gastrointestinal bleeding, such as black or tarry stools, and to have their blood pressure monitored regularly.

Phenylephrine HCl is a sympathomimetic agent that can interact with other medications affecting the cardiovascular system. It may potentiate the effects of other vasoconstrictors and should be used cautiously in patients taking monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants, as these can enhance the pressor effects of phenylephrine. Patients with pre-existing cardiovascular conditions should be monitored for changes in blood pressure and heart rate.

It is crucial for both patients and prescribers to be aware of these potential interactions when considering the use of Cyclosporine A 2%/Ketoprofen 2.5%/Phenylephrine HCl 0.1% Topical Cream. A thorough review of the patient's current medication regimen and medical history is recommended to identify any potential risks. If you have any questions or concerns about this formulation or its interactions, please reach out to us for further guidance and support.

This topical cream formulation combines three active ingredients: Cyclosporine A, Ketoprofen, and Phenylephrine HCl, each contributing to the treatment of specific disease states through distinct mechanisms of action. The semisolid preparation is dispensed via a pump mechanism, ensuring a convenient and controlled application on the skin, which facilitates localized treatment and absorption of the active ingredients.

Cyclosporine A is an immunosuppressant that works by inhibiting the activity of calcineurin, a protein phosphatase involved in the activation of T-cells. By suppressing the immune response, Cyclosporine A helps reduce inflammation and is particularly effective in treating inflammatory skin conditions such as psoriasis and eczema. Its topical application allows for targeted action at the site of inflammation, minimizing systemic exposure and potential side effects associated with oral administration.

Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that provides relief from pain and inflammation by inhibiting the cyclooxygenase (COX) enzymes, which are responsible for the synthesis of prostaglandins. Prostaglandins are lipid compounds that mediate inflammation and pain. By reducing their production, Ketoprofen alleviates symptoms associated with conditions like arthritis, musculoskeletal pain, and other inflammatory disorders. The topical delivery of Ketoprofen ensures that the drug acts directly at the site of pain, offering effective relief while minimizing systemic absorption and the risk of gastrointestinal side effects commonly associated with oral NSAIDs.

Phenylephrine HCl is a sympathomimetic agent that primarily acts as a selective alpha-1 adrenergic receptor agonist. Its vasoconstrictive properties help reduce swelling and congestion by constricting blood vessels in the affected area. This action is beneficial in conditions where localized vasodilation contributes to symptoms, such as in certain dermatological conditions where reducing redness and edema is desired. The inclusion of Phenylephrine HCl in this formulation enhances the overall therapeutic effect by addressing vascular components of inflammation and discomfort.

The combination of these three active ingredients in a single topical cream provides a multifaceted approach to managing inflammatory and painful skin conditions. By delivering the medication directly to the affected area, the formulation maximizes therapeutic efficacy while minimizing systemic exposure and potential side effects. This targeted approach is particularly advantageous for patients who require localized treatment without the complications associated with systemic drug administration.

For prescribers, this formulation offers a versatile treatment option that can be tailored to the specific needs of patients with inflammatory skin conditions, musculoskeletal pain, or other localized issues. The pump mechanism ensures precise dosing and ease of use, promoting adherence to treatment regimens. Patients benefit from the convenience and effectiveness of a topical therapy that addresses multiple aspects of their condition.

If you have any questions or need further information about this formulation, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to assist you with any inquiries or concerns you may have.

The Cyclosporine A 2%/Ketoprofen 2.5%/Phenylephrine HCl 0.1% topical cream, dispensed in a pump mechanism, is primarily formulated for localized treatment of inflammatory and pain-related conditions. However, beyond its primary indications, this formulation may have other potential uses that could be beneficial for both patients and prescribers to consider. Cyclosporine A, an immunosuppressant, can be utilized in managing localized autoimmune skin disorders, such as localized scleroderma or vitiligo, where immune modulation is desired to reduce disease activity. Ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID), may be used in conditions involving localized pain and inflammation, such as tendinitis or bursitis, providing targeted relief without systemic side effects associated with oral NSAIDs. Phenylephrine HCl, a vasoconstrictor, can be beneficial in reducing localized swelling and redness, potentially aiding in conditions like rosacea or post-procedural erythema.

For patients experiencing chronic pain conditions, this combination cream may offer a multifaceted approach by addressing inflammation, immune response, and vascular components simultaneously. This can be particularly advantageous in conditions where multiple pathways contribute to symptomatology, such as in certain neuropathic pain syndromes or complex regional pain syndrome (CRPS). Additionally, the topical route of administration allows for direct application to affected areas, minimizing systemic exposure and reducing the risk of systemic side effects, which is a significant consideration for patients with comorbidities or those taking multiple medications.

Prescribers may find this formulation useful in cases where traditional therapies have been inadequate or where patients are unable to tolerate systemic medications. The ability to adjust the concentration of each active ingredient in a compounded formulation allows for personalized treatment plans tailored to the specific needs of the patient. Furthermore, the pump mechanism ensures precise dosing and ease of use, enhancing patient compliance and treatment outcomes. As with any compounded medication, it is essential for prescribers to consider the individual patient's medical history, potential drug interactions, and specific condition being treated.

If you have any questions or require further information about the potential uses of this formulation, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to assist you in optimizing patient care through personalized medication solutions.